))
Health411-Cancer Therapeutics with Greg Bosch
Manage episode 379822988 series 3236776
Content provided by Dr. Jonathan Karp. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr. Jonathan Karp or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode of Health411, host Dr. Jonathan Karp and producer Daniel Geller discuss Panavance Therapeutics with Chairman and CEO Greg Bosch. Panavance is focused on the compound GP-2250, a molecule with broad applications in cancer treatment. During the interview, Mr. Bosch elaborates on the groundbreaking potential of GP-2250, explaining how it targets specific cancer cells while minimizing damage to healthy tissue. He also shared insights into Panavance's rigorous clinical trials and its commitment to advancing personalized therapies for cancer patients. Tune in to learn more about the promising future of GP-2250 and its potential to revolutionize cancer treatment.
231 episodes
Share
